NanoViricides Inc. (NNVC)

[arvitar]

In order to generate revenue, NNVC must have an approved drug they can sell.


Before NNVC can do that, it must first identify a lead molecule, and get an approved IND-application.


Unfortunately, the fact remains that in all of human history, there has never been a single instance of a management team first failing for 11 years to get a single preclinical candidate IND-approved, and then suddenly accomplishing that.

There's no reason to believe that NNVC will be the first.

Indeed, given the age and unremarkable careers of its management team, there's plenty of reason to believe that NNVC won't be the first to set such historic precedent.